VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company says is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). This breakthrough addresses a longstanding challenge in liquid biopsy: separating cancer-derived DNA from the large background of healthy cell-free DNA. The technology creates highly enriched tumor DNA datasets, enabling more accurate cancer detection and monitoring.
The publication describes a two-step process that combines physical sample enrichment with bioinformatic filtering to produce sequencing datasets with greater than 99% purity. Early validation studies demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have produced encouraging findings, according to the company.
VolitionRx is now advancing larger validation studies, working with oncology key opinion leaders, and expanding patent protection for the technology as it explores commercialization opportunities. The company is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications, totaling $36 billion.
“This peer-reviewed publication is a significant milestone for our Capture-Seq technology,” said a company spokesperson. “We believe it has the potential to improve cancer detection and monitoring, ultimately saving lives and improving patient outcomes.”
The implications of this technology are vast. For the healthcare industry, it could lead to more sensitive and specific liquid biopsy tests, reducing the need for invasive tissue biopsies and enabling earlier cancer detection. For patients, it could mean more timely interventions and better monitoring of treatment response and disease recurrence. For the broader market, the technology could unlock new opportunities in personalized medicine and cancer management, potentially reshaping standard of care.
VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, it is developing and commercializing simple, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more information, visit the company’s website at https://volition.com/.
